97066 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans Blood coagulation or fibrinolysis factors
Sub-classes:HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#2HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#3HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#4HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#5ANTITHROMBIN IN STROKE
#6PLASMA FRACTIONATION UTILIZING SPRAY-DRIED HUMAN PLASMA
#7Compositions for Treating Pathological Calcification Conditions, and Methods Using Same
#8RECOMBINANT VITAMIN K DEPENDENT PROTEINS WITH HIGH SIALIC ACID CONTENT AND METHODS OF PREPARING SAME
#9HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#10HYBRID MOLECULE COMPRISING AN ANTIBODY FC FRAGMENT AND AT LEAST ONE FIBRIN-DERIVED CITRULLINATED PEPTIDE, AND USES THEREOF
#11SYNTHETIC PLATELETS
#12Therapeutic Biologic For Treatment Of Glioblastoma
#13MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF
#14TARGETED ANTICOAGULANT
#15IMPROVED MEDIA FOR THE EXPRESSION OF RECOMBINANT VITAMIN K-DEPENDENT PROTEINS
#16IL-17A-BINDING POLYPEPTIDES
#17Vascular Extracellular Matrix Hydrogel
#18METHODS OF PRODUCING LONG-ACTING COAGULATION FACTORS
#19MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
#20BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR P-SELECTIN
#21EXTENDED RECOMBINANT POLYPEPTIDES AND COMPOSITIONS COMPRISING SAME
#22MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE
#23DIAGNOSIS AND TREATMENT OF ANTI-PF4 INDUCED THROMBOCYTOPENIA
#24MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS
#25MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
#26HYBRID MOLECULE COMPRISING A FIBRIN-DERIVED CITRULLINATED PEPTIDE AND AN ANTIBODY OR ANTIBODY FRAGMENT WHICH BINDS TO CD38 AND/OR CD138, AND USES THEREOF
#27COMPOSITION COMPRISING RECOMBINANT Gplba RECEPTOR PROTEIN
#28IMMUNOGLOBULIN FUSION PROTEINS AND USES THEREOF
#29METHOD FOR EXPRESSING AND PURIFYING PROTEIN BY USING CSQ-TAG
#30IMMUNOGLOBULIN FUSION PROTEINS
#31IMMUNOGLOBULIN FUSION PROTEINS AND USES THEREOF
#32MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF
#33MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS
#34MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF
#35MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF
#36RECOMBINANT MICROALGAE ABLE TO PRODUCE KTTKS PEPTIDES, POLYPEPTIDES, OR PROTEINS AND THEIR DERIVATIVES AND ASSOCIATED METHOD AND USES THEREOF
#37Synthetic platelets
#38Non-human animals comprising a humanized coagulation factor 12 locus
#39HEMOSTATIC NANOPARTICLES FOR THE TREATMENT OF NON-COMPRESSIBLE HEMORRHAGE AND INTERNAL BLEEDING
#40A PROCESS FOR THE PURIFICATION OF PROTHROMBIN COMPLEX CONCENTRATE (PCC) AND FIX FROM COMPLETE PLASMA OR CRYO-POOR PLASMA
#41HIGH-ACTIVITY BLOOD COAGULATION FACTOR XI MUTANT ALA570THR
#42BLOOD COAGULATION TEST REAGENT, AND BLOOD COAGULATION TEST METHOD
#43REGULATORY T CELL EPITOPES
#44RECOMBINANT VITAMIN K DEPENDENT PROTEINS WITH HIGH SIALIC ACID CONTENT AND METHODS OF PREPARING SAME
#45MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF
#46METHOD OF PREPARING FIBRONECTIN CONCENTRATES
#47Methods and compositions for modified factor IX fusion proteins
#48ANTI-VWF D'D3 SINGLE-DOMAIN ANTIBODIES AND POLYPEPTIDES COMPRISING THEREOF
#49NON-VIRAL DNA VECTORS AND USES THEREOF FOR EXPRESSING FACTOR IX THERAPEUTICS
#50RECOMBINANT MICROALGAE ABLE TO PRODUCE KTTKS PEPTIDES, POLYPEPTIDES, OR PROTEINS AND THEIR DERIVATIVES AND ASSOCIATED METHOD AND USES THEREOF
#51Multifunctional Heteromultimeric Constructs
#52MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF
#53Translatable molecules and synthesis thereof
#54IMMUNOGLOBULIN CHIMERIC MONOMER-DIMER HYBRIDS
#55Therapeutic Biologic For Treatment Of Hepatocellular Carcinoma
#56Bicyclic peptide ligands specific for P-selectin
#57Vascular extracellular matrix hydrogel
#58METHODS AND COMPOSITIONS FOR TREATING CANCER WITH COLLAGEN BINDING DRUG CARRIERS
#59FIBRIN BIOPOLYMER FORMATION AND APPLICATION DEVICE
#60SYNTHETIC PRODUCTION OF SINGLE-STRANDED ADENO ASSOCIATED VIRAL DNA VECTORS
#61RED BLOOD CELLS EXPRESSING VON WILLEBRAND FACTOR PROTEASE AND METHODS OF USE THEREOF
#62TARGETED ANTICOAGULANT
#63Long-acting coagulation factors and methods of producing same
#64Compositions for treating pathological calcification conditions, and methods using same
#65PLASMA FRACTIONATION UTILIZING SPRAY-DRIED HUMAN PLASMA
#66ANTI-GLYCOPROTEIN IIb/IIIa ANTIBODIES
#67METHODS AND COMPOSITIONS FOR MODIFIED FACTOR IX PROTEINS
#68METHODS OF USING FIX POLYPEPTIDES
#69Virus Filtration of Liquid Factor VII Compositions
#70Composition comprising recombinant GPlbα receptor protein
#71IMMUNOGLOBULIN CHIMERIC MONOMER-DIMER HYBRIDS
#72METHOD FOR PURIFYING AND QUANTIFYING THROMBIN AND ITS DEGRADATION POLYPEPTIDES
#73COMPOSITIONS AND METHODS FOR ANTI-THROMBOTIC AND HEMOSTATIC THERAPIES
#74Optimized Liver-Specific Expression Systems for FVIII and FIX
#75CHIMERIC CLOTTING FACTORS
#76CLOTTING FACTOR-FC CHIMERIC PROTEINS TO TREAT HEMOPHILIA
#77METHODS AND COMPOSITIONS FOR MODIFYING THE VON WILLEBRAND FACTOR GENE
#78REGULATORY T CELL EPITOPES
#79MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE
#80PROCESSABLE SINGLE CHAIN MOLECULES AND POLYPEPTIDES MADE USING SAME
#81HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#82METHOD OF PURIFYING THERAPEUTIC PROTEINS
#83Extended recombinant polypeptides and compositions comprising same
#84Chromatography resin and uses thereof
#85Polypeptides modulating SIGLEC dependent immune responses
#86Methods of treatment of IL-17A associated conditions
#87GENE THERAPY FOR HEMOPHILIA B WITH A CHIMERIC AAV CAPSID VECTOR ENCODING MODIFIED FACTOR IX POLYPEPTIDES
#88FACTOR IX FUSION PROTEINS AND METHODS OF MAKING AND USING SAME
#89COMPOSITIONS AND METHODS FOR TREATMENT OF OCULAR DISEASES
#90FACTOR IX-TRANSFERRIN FUSION PROTEINS
#91VIRAL VECTORS ENCODING RECOMBINANT FIX WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA B
#92MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
#93GLA DOMAINS AS TARGETING AGENTS
#94METHODS AND COMPOSITIONS FOR TREATMENT OF HEMOPHILIA
#95IN VIVO PRODUCTION OF PROTEINS
#96Multi-chain chimeric polypeptides and uses thereof
#97Multi-chain chimeric polypeptides and uses thereof
#98Method of targeting exosomes
#99GLA DOMAINS AS THERAPEUTIC AGENTS
#100Tumor marker, and method for collecting and detecting tumor cell in distinction from contaminant cell
#101A METHOD OF INTRACELLULAR DELIVERY
#102DELIVERY OF PAYLOADS TO STEM CELLS
#103Factor VII Composition Having a Substantially Homogeneous Isoelectric Point
#104METHODS AND COMPOSITIONS FOR MODIFIED FACTOR IX PROTEINS
#105ANTI-GLYCOPROTEIN IIb/IIIa ANTIBODIES
#106Long-acting coagulation factors and methods of producing same
#107MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS
#108TISSUE FACTOR-TARGETING CAR-NK AND CAR-T CELL THERAPY
#109Non-human animals comprising a humanized coagulation factor 12 locus
#110MUTATED FACTOR X POLYPEPTIDES AND USES THEREOF FOR THE TREATMENT OF HAEMOPHILIA
#111Treatment of monogenetic disorders
#112METHODS AND COMPOSITIONS RELATED TO LONG HALF-LIFE COAGULATION COMPLEXES
#113Factor VII composition having a substantially homogenous isoelectric point
#114METHOD FOR INCREASING THE HETEROGENEITY OF O-GLYCOSYLATION OF RECOMBINANT FACTOR VII
#115Long-acting coagulation factors and methods of producing same
#116Virus filtration of liquid factor VII compositions
#117MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
#118Methods for treating pseudoxanthoma elasticum (PXE)
#119Anti-VWF D'D3 single-domain antibodies fuse to clotting factors
#120USE OF LENTIVIRAL VECTORS EXPRESSING FACTOR IX
#121POLYPEPTIDES
#122Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
#123Human coagulation factor IX (FIX) fusion protein, preparation method therefor, and use thereof
#124Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
#125Compositions for treating pathological calcification conditions, and methods using same
#126PANCREATIC CANCER TARGETS AND USES THEREOF
#127Method for purifying and quantifying thrombin and its degradation polypeptides
#12821-DAY DOSING REGIMEN FOR FUSION PROTEINS COMPRISING FACTOR IX AND HUMAN ALBUMIN FOR PROPHYLACTIC TREATMENT OF HEMOPHILIA AND METHODS THEREOF
#129PROTEOLYTICALLY CLEAVABLE FUSION PROTEINS WITH HIGH MOLAR SPECIFIC ACTIVITY
#130METHODS AND COMPOSITIONS FOR MODIFIED FACTOR IX PROTEINS
#131PIVKA-II MEASUREMENT METHOD, MEASUREMENT REAGENT, AND MEASUREMENT KIT
#132Immunoglobulin chimeric monomer-dimer hybrids
#133Multi-chain chimeric polypeptides and uses thereof
#134Synthetic platelets
#135Modified polynucleotides for the production of secreted proteins
#136Fusion peptide comprising thrombus-targeting peptide, ferritin fragment and thrombolytic peptide, and use thereof
#137Multifunctional heteromultimeric constructs
#138TARGETED ANTICOAGULANT
#139Therapeutic biologic for treatment of hepatocellular carcinoma
#140PEPTIDES DERIVED FROM KININOGEN-1 FOR PROTEIN DRUGS IN VIVO HALF-LIFE EXTENSIONS
#141Modified polynucleotides for the production of secreted proteins
#142In vivo production of proteins
#143CANCER BINDING CHROMATIC PEPTIDES THAT ARE TARGETED FOR DISINTEGRATION BY RADIANT ENERGY
#144Treatment and prevention of remote ischemia-reperfusion injury
#145RECOMBINANT VITAMIN K DEPENDENT PROTEINS WITH HIGH SIALIC ACID CONTENT AND METHODS OF PREPARING SAME
#146METHODS AND COMPOSITIONS FOR MODIFIED FACTOR IX PROTEINS
#147Cell-associated secretion-enhancing fusion proteins
#148Compositions for treating pathological calcification conditions, and methods using same
#149Methods and kits for assessing Heparanase procoagulant activity, compositions comprising Heparanase, and methods for the treatment of coagulation-related disorders
#150Hydrophobic charge induction chromatographic protein depleted solution
#151Polypeptides modulating SIGLEC dependent immune responses
#152Factor VIII polymer conjugates
#153Glycosylated VWF fusion proteins with improved pharmacokinetics
#154COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH NEOVASCULARIZATION
#155Peptides that inhibit binding of EPCR to its ligand to treat inflammation
#156Compositions and methods for thrombin generation assay
#157Methods and compositions for reducing infectivity of virus particles comprising an ERGIC-53 polypeptide
#158GLA domains as therapeutic agents
#159Anti-VWF D'D3 single-domain antibodies and methods of use
#160Coagulation factor-targeting to TREM-like transcript 1 (TLT-1) on activated platelets
#161Targeting tissue factor to activated platelets
#162Synthetic platelets
#163Long-acting coagulation factors and methods of producing same
#164Virus filtration of liquid factor VII compositions
#165STABILIZING AGENT FOR PHARMACEUTICAL PROTEINS
#166Compositions and methods for modulating factor IX function
#167Vascular extracellular matrix hydrogel
#168Media for the expression of recombinant vitamin K-dependent proteins
#169Anti-coagulation factor XI antibodies
#170Therapeutic biologic for treatment of hepatocellular carcinoma
#171METHODS AND COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH PATHOLOGICAL NEOVASCULARIZATION
#172Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia B
#173Translatable molecules and synthesis thereof
#174Ligand-guided phagocytosis based therapy for treatment of Alzheimer's disease and other neurodegenerative diseases
#175Processable single chain molecules and polypeptides made using same
#176Polypeptide
#177Modified Polynucleotides for the production of biologics and proteins associated with human disease
#178Methods and compositions for modified factor IX fusion proteins
#179Polypeptide
#180MODIFIED BLOOD CLOTTING FACTORS AND METHODS OF USE
#181Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
#182PROTEASE-REGULATED ANTIBODIES
#183Extended recombinant polypeptides and compositions comprising same
#184Mutated immunoglobulin-binding polypeptides
#185CLOTTING FACTOR-FC CHIMERIC PROTEINS TO TREAT HEMOPHILIA
#186Methods and compositions related to long half-life coagulation complexes
#187Method for purifying and quantifying thrombin and its degradation polypeptides
#188MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
#189Polypeptides
#190RECOMBINANT SOLUBLE HUMAN TISSUE FACTOR, METHOD OF ITS PRODUCTION AND USES THEREOF
#191Long-acting coagulation factors and methods of producing same
#192MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
#193Optimized liver-specific expression systems for FVIII and FIX
#194Synthetic platelets
#195Compositions for treating pathological calcification conditions, and methods using same
#196Compositions for treating pathological calcification conditions, and methods using same
#197Compositions for treating pathological calcification conditions, methods, and host cells using the same
#198O-linked glycoforms of polypeptides and method to manufacture them
#199Messenger UNA molecules and uses thereof
#200Methods of using FIX polypeptides
#201Modified polynucleotides for the production of oncology-related proteins and peptides
#202Mutated factor X polypeptides and uses thereof for the treatment of haemophilia
#203Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
#204IL-17A-binding polypeptides
#205In vivo production of proteins
#206Compositions for treating pathological calcification conditions, and methods using same
#207Compositions for treating pathological calcification conditions, and methods using same
#208Mutated immunoglobulin-binding polypeptides
#209Methods and kits for measuring von Willebrand factor
#210ENDOSOMAL ESCAPE DOMAINS FOR DELIVERY OF MACROMOLECULES INTO CELLS
#211Immunoglobulin chimeric monomer-dimer hybrids
#212Anti-coagulation factor XI antibodies
#213PANCREATIC CANCER TARGETS AND USES THEREOF
#214IL-6-binding polypeptide complex
#215Recombinant RNA particles and methods of producing proteins
#216Chimeric clotting factors
#217Extended recombinant polypeptides and compositions comprising same
#218Peptides and methods of use
#219MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
#220Therapeutic biologic for treatment of hepatocellular carcinoma
#221Modified polynucleotides for the production of secreted proteins
#222Method for determining FXIII levels as a prognostic biomarker in acute myocardial infarction
#223Immunoglobulin fusion proteins and uses thereof
#224IMMUNOGLOBULIN FUSION PROTEINS AND USES THEREOF
#225Methods and kits for assessing heparanase procoagulant activity, compositions comprising heparanase, and methods for the treatment of coagulation related disorders
#226Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
#227Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation
#228Targeting tissue factor to activated platelets
#229Stabilizing agent for pharmaceutical proteins
#230Long-acting coagulation factors and methods of producing same
#231Method for purifying and quantifying thrombin and its degradation polypeptides
#232Compositions and methods for modulating thrombin generation
#233RECOMBINANT PLATELET COLLAGEN RECEPTOR GLYCOPROTEIN VI AND ITS PHARMACEUTICAL USE
#234Mutated immunoglobulin-binding polypeptides
#235Mutated immunoglobulin-binding polypeptides
#236Mutated immunoglobulin-binding polypeptides
#237Transgenic factor VII having a specific N-glycosylation and substantially homogenous isoelectric point
#238Method for purifying active GLA-domain coagulation proteins
#239Human coagulation factor light chain protein and use of the same
#240Gla domains as targeting agents
#241Long-acting coagulation factors and methods of producing same
#242Modified polynucleotides for the production of biologics and proteins associated with human disease
#243INDUCTION OF ANTIGEN-SPECIFIC TOLERANCE
#244Purification method for vitamin K dependent proteins by anion exchange chromatography
#245Polypeptides
#246Gla domains as targeting agents
#247Antidotes for factor XA inhibitors and methods of using the same
#248Method for screening mutant microorganism overproducing target metabolite using synthetic suicide genetic circuit
#249Modified polynucleotides for the production of secreted proteins
#250Long-acting coagulation factors and methods of producing same
#251Hydrophobic charge induction chromatographic depletion of a protein from a solution
#252Synthetic platelets
#253Peptides and methods of use
#254Methods and kits for measuring von Willebrand factor
#255PIVKA-II measurement method, measurement reagent, and measurement kit
#256Methods and kits for measuring von Willebrand factor
#257Therapeutic agent for epithelial and endothelial injury
#258Method of purifying therapeutic proteins
#259Therapeutic biologic for treatment of hepatocellular carcinoma
#260Immunoglobulin chimeric monomer-dimer hybrids
#261Miniature swine transgenic for one or more coagulation factors
#262Coagulation factor VII polypeptides
#263Method for evaluating ischemic heart disease by assaying complement factor H or D
#264Therapeutic agents comprising fusions of growth hormone and elastic peptides
#265Composition and dressing for wound treatment
#266Long-acting coagulation factors and methods of producing same
#267Thrombin/plasmin-regulated antibodies that bind TFPI
#268Simukunin
#269Modified factor VII or factor VIIa polypeptides
#270Alpha-1 antitrypsin variant, preparation method thereof and use thereof
#271Method of producing recombinant vitamin K dependent proteins
#272Methods for processing coagulation factors
#273Pro-coagulant compounds and methods of use thereof
#274Extended recombinant polypeptides and compositions comprising same
#275Thermostable Inhibitors of Activation of the Blood Clotting System Through Contact with Foreign Surfaces
#276Recombinant baculovirus and use thereof
#277Compositions and methods for modulating thrombin generation
#278Stabilizing agent for pharmaceutical proteins
#279Therapeutic agents comprising fusions of insulin and elastic peptides
#280Single component fibrin hemostat
#281Methods and kits for assessing heparanase procoagulant activity, compositions comprising heparanase, and methods for the treatment of coagulation related disorders
#282Locally-active anticoagulants and anti-inflammatory agents
#283Modified vitamin K-dependent polypeptides
#284Synthetic platelets
#285Selective αβreceptor peptide antagonist for therapeutic and diagnostic applications
#286Procedure for biphasic preparation of liposomes and application thereof in manufacturing diagnostic reagents
#287Method for preparing a concentrate of factor XI
#288Process for the preparation of a virus-inactivated FV concentrate starting from human plasma, scalable to industrial level
#289Nucleic acids encoding modified vitamin K-dependent polypeptides
#290Methods for increasing plasmin activity and promoting plaque regression in the treatment of atherosclerosis
#291Fusion protein having factor IX activity
#292METHOD FOR EXTRACTING A PROTEIN FROM MILK
#293Long-acting coagulation factors and methods of producing same
#294Affinity chromatography matrix
#295Method for mass production of factor VII/VIIA
#296Clotting factor-Fc chimeric proteins to treat hemophilia
#297Serene protease derivatives and uses in the prevention or the treatment of blood coagulation disorders
#298Processable single chain molecules and polypeptides made using same
#299Immunoglobulin chimeric monomer-dimer hybrids
#300Heterodimeric human IgG1 polypeptides with isoelectric point modifications